AstraZeneca | AZN

AstraZeneca traded at 11,134.00 this Tuesday March 28th, decreasing 118.00 or 1.05 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 2.94 percent. Over the last 12 months, its price rose by 10.83 percent. Looking ahead, we forecast AstraZeneca to be priced at 10,796.83 by the end of this quarter and at 10,022.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
11,134.00
Daily Change
-1.05%
Yearly
10.83%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 158.25 0.71 0.45% -2.43%
Alcon AG 62.70 0.30 0.48% -16.76%
Almirall SA 8.49 -0.19 -2.13% -27.79%
Amgen 238.48 1.72 0.73% -1.27%
argenx SE 337.50 3.90 1.17% 22.15%
Artemis Alpha 305.00 -10.00 -3.17% -12.73%
AstraZeneca 11,134.00 -118.00 -1.05% 10.83%
Bayer 56.87 0.87 1.55% -8.23%
Biogen 270.25 0.27 0.10% 25.73%
Bristol-Myers Squibb 68.20 0.13 0.19% -6.87%
Fresenius Medical Care 38.28 -0.21 -0.55% -36.18%
Fresenius 23.94 -0.08 -0.33% -27.75%
Genmab 2,576.00 -28.00 -1.08% 6.98%
Gilead Sciences 80.97 1.39 1.75% 33.77%
Galapagos 33.40 -1.42 -4.08% -41.55%
GRIFOLS 8.93 -0.11 -1.19% -42.82%
GlaxoSmithKline 1,421.00 -2.60 -0.18% -13.43%
Hikma Pharmaceutical 1,631.50 -26.50 -1.60% -21.18%
Eli Lilly 337.65 3.05 0.91% 17.08%
Lonza Group 533.60 -4.40 -0.82% -20.62%
Merck 170.40 -2.70 -1.56% -12.19%
Merck & Co 105.53 -1.40 -1.31% 29.37%
Novartis 83.47 1.22 1.48% 2.34%
Orion 40.38 -0.34 -0.84% -1.70%
Pfizer 40.01 -0.24 -0.60% -24.14%
Philips 15.04 -0.18 -1.17% -46.93%
Recordati 39.24 -0.72 -1.80% -16.46%
Regeneron Pharmaceuticals 826.97 6.56 0.80% 18.40%
Roche Holding 256.95 0.05 0.02% -31.07%
Sanofi 100.00 1.56 1.58% 8.70%
UCB 80.36 0.12 0.15% -23.97%

Indexes Price Day Year
GB100 7484 12.48 0.17% -0.70%

AstraZeneca
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.